-$0.34 EPS Expected for Kadmon Holdings Inc (KDMN) This Quarter

Wall Street brokerages expect Kadmon Holdings Inc (NYSE:KDMN) to post earnings per share of ($0.34) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Kadmon’s earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.26). Kadmon posted earnings per share of ($0.50) in the same quarter last year, which would suggest a positive year over year growth rate of 32%. The company is scheduled to report its next quarterly earnings report on Wednesday, March 28th.

According to Zacks, analysts expect that Kadmon will report full year earnings of ($1.62) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($1.51). For the next year, analysts anticipate that the firm will report earnings of ($1.49) per share, with EPS estimates ranging from ($2.09) to ($1.08). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Kadmon.

Several brokerages have commented on KDMN. Piper Jaffray Companies reissued a “positive” rating and set a $9.00 price target (up from $7.00) on shares of Kadmon in a research report on Tuesday. Jefferies Group boosted their price target on shares of Kadmon to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research cut shares of Kadmon from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Kadmon in a research report on Friday, December 15th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Kadmon currently has an average rating of “Hold” and an average target price of $10.21.

Shares of Kadmon (NYSE KDMN) traded down $0.13 during trading hours on Thursday, reaching $3.66. 272,694 shares of the company’s stock traded hands, compared to its average volume of 1,363,741. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.86. The company has a market cap of $299.63, a PE ratio of -2.09 and a beta of 5.39.

Hedge funds have recently modified their holdings of the company. Crestline Management LP bought a new stake in shares of Kadmon in the 3rd quarter valued at about $2,011,000. Sphera Funds Management LTD. bought a new stake in shares of Kadmon in the 3rd quarter valued at about $3,685,000. AE Wealth Management LLC raised its holdings in shares of Kadmon by 33.6% in the 3rd quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock valued at $1,083,000 after purchasing an additional 81,226 shares during the period. Vanguard Group Inc. raised its holdings in shares of Kadmon by 166.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after purchasing an additional 941,549 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in shares of Kadmon by 23.2% in the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock valued at $247,000 after purchasing an additional 13,923 shares during the period. 51.91% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “-$0.34 EPS Expected for Kadmon Holdings Inc (KDMN) This Quarter” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/15/0-34-eps-expected-for-kadmon-holdings-inc-kdmn-this-quarter.html.

Kadmon Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply